DrugPatentWatch Database Preview
Sandoz Inc Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?
SANDOZ INC has one hundred and thirty-four approved drugs.
There are four US patents protecting SANDOZ INC drugs. There are fourteen tentative approvals on SANDOZ INC drugs.
There are twenty patent family members on SANDOZ INC drugs in eighteen countries and two hundred and sixteen supplementary protection certificates in fifteen countries.
Summary for Sandoz Inc
| International Patents: | 20 |
| US Patents: | 4 |
| Tradenames: | 108 |
| Ingredients: | 105 |
| NDAs: | 134 |
| Patent Litigation for Sandoz Inc: | See patent lawsuits for Sandoz Inc |
| PTAB Cases with Sandoz Inc as petitioner: | See PTAB cases with Sandoz Inc as petitioner |
Drugs and US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 091465-001 | Jun 14, 2016 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | GRANISETRON HYDROCHLORIDE | granisetron hydrochloride | INJECTABLE;INJECTION | 078531-002 | Apr 30, 2009 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Sandoz Inc | FULVESTRANT | fulvestrant | INJECTABLE;INTRAMUSCULAR | 205935-001 | May 14, 2019 | AO | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | 5,196,404*PED | Start Trial |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,252,984 | Start Trial |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,311,708 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANDOZ INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
International Patents for Sandoz Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 740586 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9951273 | Start Trial |
| Portugal | 1069913 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sandoz Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0316633 | 99C0012 | Belgium | Start Trial | PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218 |
| 0502314 | C990007 | Netherlands | Start Trial | PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211 |
| 0809498 | SPC/GB10/012 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
